Financial
FY2026 revenue A$261.7m (+22.9%); underlying EBIT margin 74.9%; net income A$265.3m.
Statutory NPAT A$265.3m includes investment gain; underlying NPAT A$144.7m (+24.1%).
Pro Medicus
HQ Australia · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: PME.AX
FY2026 revenue A$261.7m (+22.9%); underlying EBIT margin 74.9%; net income A$265.3m.
Statutory NPAT A$265.3m includes investment gain; underlying NPAT A$144.7m (+24.1%).
Source: official results release · Year ended 2026-06-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | A$261.7m | +22.9% | A$196.1m | A$265.3m | Pro Medicus |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Not yet researched.
Cyber & information governance
Not yet researched.
Regulatory & clinical safety
Not yet researched.
Contract performance
Not yet researched.
Competitors
No competitors linked yet.